Article
Timolol reports for infantile hemangioma contain systemic beta- blocker signals in FAERS/openFDA
2026-08-20
Abstract excerpt
<title>Abstract</title> <p>Topical timolol is widely used for selected superficial infantile hemangiomas, but systemic beta-blocker effects remain biologically plausible in young infants. We analyzed FDA Adverse Event Reporting System reports accessed through openFDA to characterize beta-blocker reports with infantile hemangioma indications and to evaluate timolol in context. The downloaded beta-blocker/infantile...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ef657900-306e-5761-8e65-b9524f952348
- DOI
- 10.21203/rs.3.rs-10302806/v1
